Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.

Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, Griesser RH, Spackman KJ, Mendenhall M, Carlos MP, Healey B, St George K, Laplante J, Aden T, Chester S, Xu X, Gubareva LV.

Antiviral Res. 2016 Apr;128:28-35. doi: 10.1016/j.antiviral.2016.01.009. Epub 2016 Jan 22.

PMID:
26808479
2.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
3.

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Tamura D, Okomo-Adhiambo M, Mishin VP, Guo Z, Xu X, Villanueva J, Fry AM, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2015 Apr;59(4):2374-9. doi: 10.1128/AAC.04939-14. Epub 2015 Feb 2.

4.

Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.

Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Villanueva JM, Gubareva LV; 2013–14 US Influenza Antiviral Working Group.

Emerg Infect Dis. 2015 Jan;21(1):136-41. doi: 10.3201/eid2101.141006.

5.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV.

Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215. Epub 2013 Dec 2.

6.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

7.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

8.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

9.

Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.

Okomo-Adhiambo M, Sheu TG, Gubareva LV.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:44-9. doi: 10.1111/irv.12051. Review.

10.

The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

Hurt AC, Okomo-Adhiambo M, Gubareva LV.

Methods Mol Biol. 2012;865:115-25. doi: 10.1007/978-1-61779-621-0_7.

PMID:
22528156
11.

The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

Okomo-Adhiambo M, Hurt AC, Gubareva LV.

Methods Mol Biol. 2012;865:95-113. doi: 10.1007/978-1-61779-621-0_6.

PMID:
22528155
12.

Gene expression in Sinclair swine with malignant melanoma.

Okomo-Adhiambo M, Rink A, Rauw WM, Gomez-Raya L.

Animal. 2012 Feb;6(2):179-92. doi: 10.1017/S1751731111001637.

PMID:
22436175
13.

Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.

Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM; US Antiviral Resistance Surveillance Working Group.

Emerg Infect Dis. 2012 Feb;18(2):308-11. doi: 10.3201/eid1802.111466.

14.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

15.

Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.

Graitcer SB, Gubareva L, Kamimoto L, Doshi S, Vandermeer M, Louie J, Waters C, Moore Z, Sleeman K, Okomo-Adhiambo M, Marshall SA, St George K, Pan CY, LaPlante JM, Klimov A, Fry AM.

Emerg Infect Dis. 2011 Feb;17(2):255-7. doi: 10.3201/eid1702.101724.

16.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
17.

Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 May;54(5):1834-41. doi: 10.1128/AAC.01608-09. Epub 2010 Mar 1.

18.

Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.

Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Mar;54(3):1102-10. doi: 10.1128/AAC.01417-09. Epub 2009 Dec 22.

19.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
20.

Influenza epidemiology and characterization of influenza viruses in patients seeking treatment for acute fever in Cambodia.

Blair PJ, Wierzba TF, Touch S, Vonthanak S, Xu X, Garten RJ, Okomo-Adhiambo MA, Klimov AI, Kasper MR, Putnam SD.

Epidemiol Infect. 2010 Feb;138(2):199-209. doi: 10.1017/S095026880999063X. Epub 2009 Aug 24.

PMID:
19698213
21.

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.

Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ.

Science. 2009 Jul 10;325(5937):197-201. doi: 10.1126/science.1176225. Epub 2009 May 22.

22.

Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay.

Guo L, Garten RJ, Foust AS, Sessions WM, Okomo-Adhiambo M, Gubareva LV, Klimov AI, Xu X.

Antiviral Res. 2009 Apr;82(1):29-33. doi: 10.1016/j.antiviral.2009.01.004. Epub 2009 Jan 31.

PMID:
19428592
23.

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.

Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry AM; Oseltamivir-Resistance Working Group.

JAMA. 2009 Mar 11;301(10):1034-41. doi: 10.1001/jama.2009.294. Epub 2009 Mar 2.

PMID:
19255110
24.

Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.

Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, Klimov AI, Gubareva LV.

Antiviral Res. 2009 Jan;81(1):16-24. doi: 10.1016/j.antiviral.2008.08.008. Epub 2008 Oct 7.

PMID:
18835410
25.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

26.

The value of DNA paternity identification in beef cattle: examples from Nevada's free-range ranches.

Gomez-Raya L, Priest K, Rauw WM, Okomo-Adhiambo M, Thain D, Bruce B, Rink A, Torell R, Grellman L, Narayanan R, Beattie CW.

J Anim Sci. 2008 Jan;86(1):17-24. Epub 2007 Sep 18.

PMID:
17878273
27.

Modeling inheritance of malignant melanoma with DNA markers in Sinclair swine.

Gomez-Raya L, Okomo-Adhiambo M, Beattie C, Osborne K, Rink A, Rauw WM.

Genetics. 2007 May;176(1):585-97.

28.

Supplemental Content

Loading ...
Support Center